These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9771615)

  • 41. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
    Wang-Smith L; Fort J; Zhang Y; Sostek M
    J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats.
    Adrian JE; Kamps JA; Scherphof GL; Meijer DK; van Loenen-Weemaes AM; Reker-Smit C; Terpstra P; Poelstra K
    Biochim Biophys Acta; 2007 Jun; 1768(6):1430-9. PubMed ID: 17493581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.
    Kamps JA; Swart PJ; Morselt HW; Pauwels R; De Béthune MP; De Clercq E; Meijer DK; Scherphof GL
    Biochim Biophys Acta; 1996 Jan; 1278(2):183-90. PubMed ID: 8593275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereoselective disposition of naproxen glucuronide in the rat.
    Iwaki M; Bischer A; Nguyen AC; McDonagh AF; Benet LZ
    Drug Metab Dispos; 1995 Oct; 23(10):1099-103. PubMed ID: 8654198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine.
    Biessen EA; Beuting DM; Vietsch H; Bijsterbosch MK; Van Berkel TJ
    J Hepatol; 1994 Nov; 21(5):806-15. PubMed ID: 7890898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module.
    Lejon S; Cramer JF; Nordberg P
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Feb; 64(Pt 2):64-9. PubMed ID: 18259051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
    Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
    Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
    van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J
    Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis.
    Castañeda-Hernández G; Favari L; Hoyo-Vadillo C
    Arzneimittelforschung; 1995 May; 45(5):585-9. PubMed ID: 7612058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The tissue cage in dogs--a pharmacologic model for the representation of plasma and tissue kinetics].
    Scherkl R; Hashem A; Frey HH
    Dtsch Tierarztl Wochenschr; 1996 May; 103(5):174-7. PubMed ID: 8964239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formaldehyde treated albumin contains monomeric and polymeric forms that are differently cleared by endothelial and Kupffer cells of the liver: evidence for scavenger receptor heterogeneity.
    Jansen RW; Molema G; Harms G; Kruijt JK; van Berkel TJ; Hardonk MJ; Meijer DK
    Biochem Biophys Res Commun; 1991 Oct; 180(1):23-32. PubMed ID: 1656967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracellular calcium alterations and free radical formation evaluated by flow cytometry in endotoxin-treated rat liver Kupffer and endothelial cells.
    Portolés MT; Arahuetes RM; Pagani R
    Eur J Cell Biol; 1994 Oct; 65(1):200-5. PubMed ID: 7889990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion.
    Melgert BN; Olinga P; Weert B; Slooff MJ; Meijer DK; Poelstra K; Groothuis GM
    Drug Metab Dispos; 2001 Jun; 29(6):361-7. PubMed ID: 11353741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural studies of bovine, equine, and leporine serum albumin complexes with naproxen.
    Bujacz A; Zielinski K; Sekula B
    Proteins; 2014 Sep; 82(9):2199-208. PubMed ID: 24753230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereoselective interaction of epimeric naproxen-RGD peptides with human serum albumin.
    González-Béjar M; Alarcón E; Poblete H; Scaiano JC; Pérez-Prieto J
    Biomacromolecules; 2010 Sep; 11(9):2255-60. PubMed ID: 20795724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.
    Minayoshi Y; Maeda H; Yanagisawa H; Hamasaki K; Mizuta Y; Nishida K; Kinoshita R; Enoki Y; Imafuku T; Chuang VTG; Koga T; Fujiwara Y; Takeya M; Sonoda K; Wakayama T; Taguchi K; Ishima Y; Ishida T; Iwakiri Y; Tanaka M; Sasaki Y; Watanabe H; Otagiri M; Maruyama T
    Drug Deliv; 2018 Nov; 25(1):1067-1077. PubMed ID: 29688069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor.
    Beljaars L; Molema G; Schuppan D; Geerts A; De Bleser PJ; Weert B; Meijer DK; Poelstra K
    J Biol Chem; 2000 Apr; 275(17):12743-51. PubMed ID: 10777570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
    Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
    Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disposition of amphotericin B in the isolated perfused rat liver.
    Hong Y; Ramzan I; McLachlan AJ
    J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.